Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [41] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Bao, Xuhui
    Liang, Yongjun
    Chang, Hanman
    Cai, Tianji
    Feng, Baijie
    Gordon, Konstantin
    Zhu, Yuekun
    Shi, Hailian
    He, Yundong
    Xie, Liyi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [42] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After LDL Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION, 2013, 128 (22)
  • [43] Role and regulation of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in the small intestine
    Leblond, Francois
    Precourt, Louis-Philippe
    Delvin, Edgard
    Elchebly, Mounib
    Seidah, Nabil
    Ziv, Ehud
    Levy, Emile
    FASEB JOURNAL, 2008, 22
  • [44] Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
    Xuhui Bao
    Yongjun Liang
    Hanman Chang
    Tianji Cai
    Baijie Feng
    Konstantin Gordon
    Yuekun Zhu
    Hailian Shi
    Yundong He
    Liyi Xie
    Signal Transduction and Targeted Therapy, 9
  • [45] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O'Connell, Emma M.
    Lohoff, Falk W.
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [46] Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis
    Lu, Xinjie
    CURRENT DRUG TARGETS, 2019, 20 (10) : 1029 - 1040
  • [47] Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
    Jabor, Antonin
    Vackova, Tereza
    Kubicek, Zdenek
    Komrskova, Jitka
    Protus, Marek
    Franekova, Janka
    CLINICA CHIMICA ACTA, 2021, 521 : 59 - 63
  • [48] Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and risk of cardiovascular events in atrial fibrillation
    Pastori, D.
    Carnevale, R.
    Nocella, C.
    Bartimoccia, S.
    Vicario, T.
    Menichelli, D.
    Violi, F.
    Pignatelli, P.
    EUROPEAN HEART JOURNAL, 2017, 38 : 382 - 382
  • [49] Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
    Tavori, Hagai
    Giunzioni, Ilaria
    Linton, MacRae F.
    Fazio, Sergio
    CIRCULATION RESEARCH, 2013, 113 (12) : 1290 - +
  • [50] Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Bhattacharya, Anindita
    Chowdhury, Abhirup
    Chaudhury, Koel
    Shukla, Praphulla Chandra
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
12345